These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37612246)

  • 1. Study design for restricted mean time analysis of recurrent events and death.
    Mao L
    Biometrics; 2023 Dec; 79(4):3701-3714. PubMed ID: 37612246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On restricted mean time in favor of treatment.
    Mao L
    Biometrics; 2023 Mar; 79(1):61-72. PubMed ID: 34562019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Power and Sample Size Calculations for the Restricted Mean Time Analysis of Prioritized Composite Endpoints.
    Mao L
    Stat Biopharm Res; 2023; 15(3):540-548. PubMed ID: 37663164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonparametric estimation in an illness-death model with component-wise censoring.
    Eaton A; Sun Y; Neaton J; Luo X
    Biometrics; 2022 Sep; 78(3):1168-1180. PubMed ID: 33914913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints.
    Cortés Martínez J; Geskus RB; Kim K; Melis GG
    BMC Med Res Methodol; 2021 May; 21(1):99. PubMed ID: 33957892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonparametric inference of general while-alive estimands for recurrent events.
    Mao L
    Biometrics; 2023 Sep; 79(3):1749-1760. PubMed ID: 35731993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simulation approach for power calculation in large cohort studies based on multistate models.
    Jenny B; Beyersmann J; Schumacher M
    Biom J; 2018 Jul; 60(4):671-686. PubMed ID: 29718579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of nonparametric estimators of the expected number of recurrent events.
    Erdmann A; Beyersmann J; Bluhmki E
    Pharm Stat; 2024; 23(3):339-369. PubMed ID: 38153191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.
    Claggett B; Pocock S; Wei LJ; Pfeffer MA; McMurray JJV; Solomon SD
    Circulation; 2018 Aug; 138(6):570-577. PubMed ID: 29588314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size formula for general win ratio analysis.
    Mao L; Kim K; Miao X
    Biometrics; 2022 Sep; 78(3):1257-1268. PubMed ID: 34047366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissecting the restricted mean time in favor of treatment.
    Mao L; Wang T
    J Biopharm Stat; 2024 Jan; 34(1):111-126. PubMed ID: 37224223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blinded continuous monitoring in clinical trials with recurrent event endpoints.
    Friede T; Häring DA; Schmidli H
    Pharm Stat; 2019 Jan; 18(1):54-64. PubMed ID: 30345693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and analysis of three-arm trials with negative binomially distributed endpoints.
    Mütze T; Munk A; Friede T
    Stat Med; 2016 Feb; 35(4):505-21. PubMed ID: 26388314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On recurrent-event win ratio.
    Mao L; Kim K; Li Y
    Stat Methods Med Res; 2022 Jun; 31(6):1120-1134. PubMed ID: 35345957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sample size calculation using Markov chains for a one-arm study of heroin administration routes.
    Grischott T; Valeri F; Falcato L
    J Biopharm Stat; 2021 May; 31(3):331-338. PubMed ID: 33476221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Power and sample size calculation for log-rank test with a time lag in treatment effect.
    Zhang D; Quan H
    Stat Med; 2009 Feb; 28(5):864-79. PubMed ID: 19152230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Power and sample size for dose-finding studies with survival endpoints under model uncertainty.
    Deng Q; Bai X; Liu D; Roy D; Ying Z; Lin DY
    Biometrics; 2019 Mar; 75(1):308-314. PubMed ID: 30203467
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.